• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » N30 Pharma selects Greenphire's payment tech for cystic fibrosis study

N30 Pharma selects Greenphire's payment tech for cystic fibrosis study

April 22, 2013
CenterWatch Staff

N30 Pharmaceuticals will use Greenphire's global payment technology platforms, eClinicalGPS and ClinCard, to streamline payments to investigators and subjects throughout its phase Ia/IIb cystic fibrosis study that began in March.

Greenphire's payment technology platforms will ensure that clinical trial payments from sponsor to site and from site to subjects are quick, accurate, automated and fully compliant with relevant regulations, including the Sunshine Act. N30 Pharma will use the eClinicalGPS platform to automate payments to investigative sites involved in the trial and the ClinCard platform to reimburse subjects and to arrange subject travel, thereby reducing costs and administrative complexities associated with the trial.

"N30 Pharma is excited to work with Greenphire on this important trial,” said Tom Sokolowski, CFO at N30 Pharma. “Using Greenphire's systems will ensure that our staff and investigators can focus entirely on the scientific and patient-centric elements of the study while remaining confident that payments are accurate, quick, and fully accounted for.”

Sam Whitaker , CEO and co-founder of Greenphire, said, "We are looking forward to collaborating with N30 Pharma on the company's first clinical trial in cystic fibrosis which we hope will eventually result in new, effective treatments for the disease. By using Greenphire's payment platforms to manage the payment and subject travel aspects of the trial, N30 Pharma can reduce costs and risk, remain compliant with relevant regulations and spend less time managing the logistical aspects of the study."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing